Special Issue

Drug Design and Activity Screening of Targeted Proteins

Message from the Guest Editor

Protein is the most basic structural and functional material of organisms, and it participates in almost all life activities. Its abnormal function is the cause of many major diseases, such as cancer, cardiovascular and cerebrovascular diseases, and so on. As the main target of drug action, proteins include enzymes, receptors, ion channels, and other types. Directly activating or inhibiting its function, regulating its function through the bypass, or promoting its degradation can make drugs targeting proteins have good therapeutic effects. In this Special Issue of Molecules, entitled "Drug Design and Activity Screening of Targeted Proteins", I invite manuscript submissions that focus on agents having the potential for the treatment of diseases and conditions affecting human and animal health. Original research articles or reviews that discuss the design, synthesis, activities, and mode of action of drug candidates targeting precise protein are particularly welcome.

Guest Editor

Prof. Dr. Dan Liu

Key Laboratory of Structure-based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China

Deadline for manuscript submissions

closed (31 May 2024)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/144100

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

